- Home
- TVTX vs KYMR Comparison
TVTX vs KYMR Comparison
Compare TVTX & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- KYMR
- Stock Information
- Founded
- TVTX 2008
- KYMR 2015
- Country
- TVTX United States
- KYMR United States
- Employees
- TVTX N/A
- KYMR N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- TVTX Health Care
- KYMR Health Care
- Exchange
- TVTX Nasdaq
- KYMR Nasdaq
- Market Cap
- TVTX 1.9B
- KYMR 2.2B
- IPO Year
- TVTX N/A
- KYMR 2020
- Fundamental
- Price
- TVTX $17.44
- KYMR $25.24
- Analyst Decision
- TVTX Strong Buy
- KYMR Buy
- Analyst Count
- TVTX 13
- KYMR 13
- Target Price
- TVTX $33.08
- KYMR $56.69
- AVG Volume (30 Days)
- TVTX 1.5M
- KYMR 613.3K
- Earning Date
- TVTX 05-05-2025
- KYMR 05-01-2025
- Dividend Yield
- TVTX N/A
- KYMR N/A
- EPS Growth
- TVTX N/A
- KYMR N/A
- EPS
- TVTX N/A
- KYMR N/A
- Revenue
- TVTX $233,175,000.00
- KYMR $47,072,000.00
- Revenue This Year
- TVTX $71.39
- KYMR $44.93
- Revenue Next Year
- TVTX $55.24
- KYMR N/A
- P/E Ratio
- TVTX N/A
- KYMR N/A
- Revenue Growth
- TVTX 60.55
- KYMR N/A
- 52 Week Low
- TVTX $5.12
- KYMR $24.36
- 52 Week High
- TVTX $25.29
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- TVTX 34.91
- KYMR 24.48
- Support Level
- TVTX $20.29
- KYMR $29.83
- Resistance Level
- TVTX $20.98
- KYMR $35.28
- Average True Range (ATR)
- TVTX 1.00
- KYMR 1.83
- MACD
- TVTX -0.23
- KYMR -0.60
- Stochastic Oscillator
- TVTX 2.01
- KYMR 7.89
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.